Most Popular Stories
- Case study: NYC works to manage diabetes
- 20 percent of diabetics are 100 pounds overweight, study concludes
- Verizon is the latest telecom to seek riches in mobile healthcare
- MRSA invading hospitals through outpatient traffic
- Alabama MDs say state Blue plan hasn't followed class-action agreement
- DTC pharma ads could raise Medicaid costs
Featured Jobs
-
Endocrinologist Job in Washington
StaffPointe, LLC - Seattle, WA -
Rheumatology Job in Minnesota
StaffPointe, LLC - north central, MN -
Endocrinologist Job in Indiana
StaffPointe, LLC - Indianapolis -
Family Practice Job in Washington
StaffPointe, LLC - near Spokane, WA -
Physician Assistant Job for Massachusetts
StaffPointe, LLC - west, MA
Events
- Harvard Business School 7th Healthcare Conference
January 30, 2010 - Security Audits: Is Your Organization Prepared and In Compliance?
Dec.3 at 12 pm CT
Paid Research Reports
- Pricing and Reimbursement in Key Asia Pacific Markets
- Delivery Mechanisms for Large Molecule Drugs: Successes and failures of leading technologies and key drivers for market success
- The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis
- Intellectual Property and Outsourcing in China: Minimizing risk whilst maximizing return on investment
- Health Care Equipment & Supplies: Global Industry Guide
- 2009 Trends to Watch: Healthcare Technology
FEATURES >> YouTube | Top acute-care hospitals | Women in Health IT | Top BlackBerry Apps | Commentary
TOPICS >> Stimulus | Health Reform | CMS News | Finance | EMRs | Mobile Healthcare | Hospital Leadership Blog
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 50,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
- Medicare
- health plans
- Centers for Medicare and Medicaid Services (CMS)
- Insurance
- Electronic Medical Records (EMRs)
- Food and Drug Administration (FDA)
- Department of Health and Human Services (HHS)
- Medicaid
- American Medical Association (AMA)
- healthcare system
- health reform
- prescription drugs
- pharmaceutical companies
Legislators, policy experts push for comparative effectiveness research
Some legislators and policy experts are pushing for a major change to how we examine the effectiveness of drugs. Currently all drugs are tested against placebos, assuring that they are "better than nothing," as David O. Barbe, MD and chair of the AMA Council on Medical Service points out. However, many are pushing for a federal agency to do comparative effectiveness testing.
At the moment, less than one-tenth of 1 percent of health research spending is used to test the effectiveness of products against one another. With sometimes large cost differentials between different products, and also possibly very different outcomes, how can we ignore these studies?
But some are also concerned about how cost would play into the studies. They question whether the cost should somehow be factored into the comparative effectiveness analysis: For instance, if drug A costs twice as much as drug B, should it be tested to see whether it is twice as effective as drug B?
Whether cost plays into the testing or not, though, most agree that establishing an agency and encouraging comparative effectiveness research will help with two of the key issues of the day: increasing quality and lowering costs.
To learn more about the efforts:
-read this AMNews piece
Related Articles:
CBO says EMRs won't save as much as hoped
Bill would create federal research institute
Is Britain's NICE a good or poor model for U.S.?
Related Stories
- Gov't readies $1.1B 'comparative effectiveness' center for summer
- Study: Comparative effectiveness research might improve mental health treatment
- Comparative effectiveness research becomes battleground
- Bill would create office to oversee comparative effectiveness research
- Committee makes comparative-effectiveness spending recommendations
- Oregon legislator still fighting for end-of-life benefit despite controversy
- Medical product innovation getting tougher, Moody's says
- Comparative research studies in the past haven't always had incredible results
- SPOTLIGHT: Debate blows up over comparative effectiveness research
- Cases for and against third-party oversight in healthcare
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map | List in Marketplace | Supplier MarketplaceTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2009 FierceMarkets, Inc. All rights reserved. |
![]() |





